Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Mycologia ; 110(2): 434-447, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29792784

RESUMO

In 2010-2011, a Xylaria sp. was documented growing from seeds of both Chlorocardium rodiei and Chlorocardium venenosum, a commercially valuable timber in Guyana. We conducted extensive surveys in 2015-2016, where this Xylaria sp. was observed fruiting from ca. 80% of dispersed seeds in both natural and logged forests in the Upper Demerara-Berbice, Potaro-Siparuni, and the Cuyuni-Mazaruni districts of central Guyana. Species of Xylaria are ascomycetous fungi generally characterized by black, carbonaceous, multiperitheciate ascoma commonly found growing on dead wood. Combined teleomorphic and molecular data indicate that the fungus represents a novel species, described here as Xylaria karyophthora.


Assuntos
Lauraceae/microbiologia , Sementes/microbiologia , Xylariales/classificação , Xylariales/isolamento & purificação , Actinas/genética , Florestas , Guiana , Técnicas Microbiológicas , Microscopia , Filogenia , Reação em Cadeia da Polimerase , RNA Polimerase II/genética , Análise de Sequência de DNA , Xylariales/citologia , Xylariales/genética
2.
Biomed Res Int ; 2018: 2472508, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29770328

RESUMO

Lutzomyia longipalpis is the main vector of visceral leishmaniasis (VL) in America. Physiological and molecular mechanisms of Leishmania infection in sand flies have been studied during the first gonotrophic cycle. There are few studies about these interactions during the second gonotrophic cycle mainly because of the difficulties maintaining sand flies through sequential feeds. Here we standardized conditions to perform the second blood feed efficiently, and our results show that oviposition is an essential factor for the success of multiple feeds. We evaluated the impact of the second blood meal on longevity, protein digestion, trypsin activity, and Leishmania mexicana development within L. longipalpis gut. Mortality of blood-fed females increases after second blood meal as compared to sugar-fed females. Trypsin activity was lower during the second gonotrophic cycle. However, no difference in protein intake was observed between blood meals. There was no difference in the population size of Leishmania in the gut after both blood meals. In this work, we presented an optimized protocol for obtaining sufficient numbers of sand fly females fed on a second blood meal, and we described some physiological and parasitological aspects of the second gonotrophic cycle which might influence the vectorial competence of sand flies.


Assuntos
Leishmaniose/parasitologia , Longevidade/fisiologia , Oviposição/fisiologia , Psychodidae/patogenicidade , Animais , Vetores de Doenças , Feminino , Trato Gastrointestinal/parasitologia , Insetos Vetores/fisiologia , Leishmania mexicana/patogenicidade , Leishmaniose/transmissão , Leishmaniose Cutânea/parasitologia , Leishmaniose Cutânea/transmissão , Leishmaniose Visceral/parasitologia , Leishmaniose Visceral/transmissão
3.
Rev. argent. reumatol ; 25(1): 16-20, 2014. graf, tab
Artigo em Espanhol | BINACIS | ID: bin-131774

RESUMO

Objetivos: Evaluar la evolución en el transcurso de dos años en pacientes con Lupus Eritematoso Sistémico (LES) refractarios al tratamiento inmunosupresor convencional, que recibieron Rituximab (RTX). Pacientes y métodos: Se estudiaron retrospectivamente 14 pacientes con diagnóstico de LES que recibieron tratamiento con RTX, atendidos en los servicios de Reumatología del Hospital Córdoba, Sanatorio Allende y Hospital Italiano de la ciudad de Córdoba, desde el año 2006. Se recabaron datos demográficos, diagnósticos, motivos de indicación de RTX, tasas de respuestas y eventos adversos. La dosis del mismo fue de 1 gramo día 1 y 15, luego cada 6 meses. Todos los pacientes habían recibido tratamiento con inmunosupresores: 12 ciclofosfamida, azatioprina, micofenolato mofetil y esteroides y 2 azatioprina y micofenolato mofetil. La actividad de la enfermedad fue medida por SELENA SLEDAI basalmente, a los 6, 12 y 24 meses postratamiento. El daño acumulado fue medido por SLICC solo basalmente. En los pacientes con nefropatía según clasificación ISN/RPS 2003, se analizó la proteinuria basal, a los 6, 12 y 24 meses, sedimento urinario y función renal medida por clearance de creatinina. Un valor de p <0,05 fue considerada significativa. Resultados: El número total de pacientes incluidos con diagnóstico de LES fue de 14, de los cuales 12 eran de sexo femenino (85,7%) y 2 de sexo masculino (14,3%). La edad promedio fue de 33,64 ± 10,33 años. Del total de pacientes, 9 presentaban compromiso renal, 3 compromiso hematológico (anemia hemolítica autoinmune, leucopenia, (trombocitopenia), 1 compromiso pulmonar (neumonitis lúpica aguda) y 1 artritis refractaria. De los pacientes con nefropatía, la clase histológica más frecuente fue la clase IV (proliferativa difusa) 77,8% (IC 95% 44,4-100%)


Objective: To evaluate the clinical response of RTX in refractory toother immunosuppressive drugs SLE patients. Patients and Methods: We retrospectively studied SLE patients who were treated with rituximab (RTX) at Rheumatology Units of Córdoba Hospital, Italiano Hospital and Sanatorium Allende in Córdoba city, since 2006. We studied demographic data, indication to RTX therapy, response, and adverse events. The disease activity was measured by SLEDAI and ECLAM and organ damage by SLICC at baseline andat 6, 12 and 24 months post-treatment. Patients with SLE and renal disease were analyzed baseline proteinuria, urinary sediment, renal function was measured by creatinine clearance. p <0.05 was considered statistically significant. Results:The number of patients was 14, 85.7% female with meanage of 33.64 ± 10.33 years old. 9 patients had renal involvement, 3 haematological, 1 lung involvement and severe arthritis. The basal SLEDAI was 15.93 ± 9.05, and 5.86 ± 5.57 and 2.8 ± 3.29 1 at 6and 24 months respectively (p <0,001).The level of proteinuria decreased from the baseline to 6, 12, 24 months (p=0.011), (p=0.028),(p=0.018). The main adverse reactions were infections in 3 patients(cutaneous infection, oral candidiasis, and pneumonia) and infusionsreactions in 2 cases. Conclusion: RTX could be a therapeutic option in SLE patients re-fractory to other immunosuppressive treatment.(AU)


Assuntos
Lúpus Eritematoso Sistêmico , Terapêutica
4.
Rev. argent. reumatol ; 25(1): 16-20, 2014. graf, tab
Artigo em Espanhol | LILACS | ID: lil-724756

RESUMO

Objetivos: Evaluar la evolución en el transcurso de dos años en pacientes con Lupus Eritematoso Sistémico (LES) refractarios al tratamiento inmunosupresor convencional, que recibieron Rituximab (RTX). Pacientes y métodos: Se estudiaron retrospectivamente 14 pacientes con diagnóstico de LES que recibieron tratamiento con RTX, atendidos en los servicios de Reumatología del Hospital Córdoba, Sanatorio Allende y Hospital Italiano de la ciudad de Córdoba, desde el año 2006. Se recabaron datos demográficos, diagnósticos, motivos de indicación de RTX, tasas de respuestas y eventos adversos. La dosis del mismo fue de 1 gramo día 1 y 15, luego cada 6 meses. Todos los pacientes habían recibido tratamiento con inmunosupresores: 12 ciclofosfamida, azatioprina, micofenolato mofetil y esteroides y 2 azatioprina y micofenolato mofetil. La actividad de la enfermedad fue medida por SELENA SLEDAI basalmente, a los 6, 12 y 24 meses postratamiento. El daño acumulado fue medido por SLICC solo basalmente. En los pacientes con nefropatía según clasificación ISN/RPS 2003, se analizó la proteinuria basal, a los 6, 12 y 24 meses, sedimento urinario y función renal medida por clearance de creatinina. Un valor de p <0,05 fue considerada significativa. Resultados: El número total de pacientes incluidos con diagnóstico de LES fue de 14, de los cuales 12 eran de sexo femenino (85,7%) y 2 de sexo masculino (14,3%). La edad promedio fue de 33,64 ± 10,33 años. Del total de pacientes, 9 presentaban compromiso renal, 3 compromiso hematológico (anemia hemolítica autoinmune, leucopenia, (trombocitopenia), 1 compromiso pulmonar (neumonitis lúpica aguda) y 1 artritis refractaria. De los pacientes con nefropatía, la clase histológica más frecuente fue la clase IV (proliferativa difusa) 77,8% (IC 95% 44,4-100%)


Objective: To evaluate the clinical response of RTX in refractory toother immunosuppressive drugs SLE patients. Patients and Methods: We retrospectively studied SLE patients who were treated with rituximab (RTX) at Rheumatology Units of Córdoba Hospital, Italiano Hospital and Sanatorium Allende in Córdoba city, since 2006. We studied demographic data, indication to RTX therapy, response, and adverse events. The disease activity was measured by SLEDAI and ECLAM and organ damage by SLICC at baseline andat 6, 12 and 24 months post-treatment. Patients with SLE and renal disease were analyzed baseline proteinuria, urinary sediment, renal function was measured by creatinine clearance. p <0.05 was considered statistically significant. Results:The number of patients was 14, 85.7% female with meanage of 33.64 ± 10.33 years old. 9 patients had renal involvement, 3 haematological, 1 lung involvement and severe arthritis. The basal SLEDAI was 15.93 ± 9.05, and 5.86 ± 5.57 and 2.8 ± 3.29 1 at 6and 24 months respectively (p <0,001).The level of proteinuria decreased from the baseline to 6, 12, 24 months (p=0.011), (p=0.028),(p=0.018). The main adverse reactions were infections in 3 patients(cutaneous infection, oral candidiasis, and pneumonia) and infusionsreactions in 2 cases. Conclusion: RTX could be a therapeutic option in SLE patients re-fractory to other immunosuppressive treatment.


Assuntos
Lúpus Eritematoso Sistêmico , Terapêutica
5.
Mycologia ; 105(2): 422-35, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23080024

RESUMO

Xerocomus cyaneibrunnescens, Xerocomus potaroensis, and Xerocomus parvogracilis (Boletales, Basidiomycota) are described as new species from the Pakaraima Mountains of Guyana, in the central Guiana Shield region. These boletes occur in neotropical forests dominated by ectomycorrhizal (ECM) trees in the genus Dicymbe (Fabaceae subfam. Caesalpinioideae). Each species produced basidiomata during a multi-year plot survey, and each was confirmed as an ECM symbiont with one or more leguminous host plant species in Guyana.


Assuntos
Basidiomycota/classificação , Fabaceae/microbiologia , Micorrizas/classificação , Sequência de Bases , Basidiomycota/citologia , Basidiomycota/genética , Basidiomycota/isolamento & purificação , DNA Fúngico/química , DNA Fúngico/genética , DNA Ribossômico/química , DNA Ribossômico/genética , DNA Espaçador Ribossômico/química , DNA Espaçador Ribossômico/genética , Carpóforos/citologia , Guiana , Microscopia Eletrônica de Varredura , Dados de Sequência Molecular , Micorrizas/citologia , Micorrizas/genética , Micorrizas/isolamento & purificação , Raízes de Plantas/microbiologia , Análise de Sequência de DNA , Especificidade da Espécie , Esporos Fúngicos/citologia , Simbiose , Árvores
6.
Arch Inst Pasteur Tunis ; 70(3-4): 405-18, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-7802496

RESUMO

The Lmet2 chemiluminescent DNA probe is a valuable tool for identifying parasites of the Leishmania donovani -complex in sand flies, dogs and human samples. Recent blood meals in sand flies or blood contamination of tissue samples inhibited probe sensitivity, whether radiolabelled or chemiluminescent detection systems were used. Treatment of membranes with protease before hybridisation restored positive signal. Alternatively samples could be lysed with protease and applied to membranes with a vacuum blotting apparatus. The Lmet2 protocol provides the basis for a DNA probe kit that is adaptable for use with a wide range of other probes.


Assuntos
Sondas de DNA , DNA de Protozoário , Doenças do Cão/patologia , Insetos Vetores/parasitologia , Leishmania infantum/genética , Leishmaniose Visceral/patologia , Psychodidae/parasitologia , Kit de Reagentes para Diagnóstico/normas , Manejo de Espécimes/métodos , Animais , Viés , Biópsia , Protocolos Clínicos , Modelos Animais de Doenças , Cães , Endopeptidases , Estudos de Avaliação como Assunto , Leishmania donovani , Reprodutibilidade dos Testes , Sensibilidade e Especificidade
7.
Angiology ; 42(10): 767-78, 1991 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-1952266

RESUMO

The amplitudes of photo-electric-plethysmography (PPG) tracings were significantly increased by subcutaneous injections of methacholine (MC) and diminished by injections of atropine (AT) as compared with placebo injections of multi-electrolyte solution (MES) both in 8 normal subjects and 11 patients with diabetic peripheral neuropathy. AT-containing lotion delayed healing compared with placebo in the forearms of 6 normal subjects. MC-containing lotion sped healing compared with placebo in the forearms of 6 subjects with diabetic neuropathy. Thigh incisions in 6 neuropathic patients were shown to heal faster if soaked in MES rather than saline. Healing with the MES solution was shown to be further increased by the addition of MC to the solution and to be decreased by the addition of AT. The addition of MC produced erythema and an increase in the amplitude of PPG tracings. AT solutions produced blanching and a decrease in the PPG amplitude. It was concluded that (1) the slow healing characteristic of neuropathic ulcers is associated with a loss of cholinergic nerve function; (2) cholinergic stimulation will increase capillary blood flow and promote healing while cholinergic blockade has opposite effects; (3) secondary ischemia makes the ulcers susceptible to the deleterious effects of therapeutic agents such as saline; (4) the ischemic tissue will heal faster with a balanced MES than with saline; and (5) the benefits of MES on healing are augmented in patients with diabetic neuropathy by the addition of cholinergic agents to the solution.


Assuntos
Atropina/uso terapêutico , Neuropatias Diabéticas/fisiopatologia , Úlcera do Pé/fisiopatologia , Cloreto de Metacolina/uso terapêutico , Sistema Nervoso Parassimpático/fisiologia , Cicatrização/efeitos dos fármacos , Neuropatias Diabéticas/tratamento farmacológico , Método Duplo-Cego , Feminino , Úlcera do Pé/tratamento farmacológico , Humanos , Soluções Hipertônicas/uso terapêutico , Masculino , Sistema Nervoso Parassimpático/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA